An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

the most successful PCSK9 inhibitors have been biologics — to date, two monoclonal antibodies (mAbs; alirocumab and evolocumab) and a small interfering RNA (siRNA; inclisiran). [Robinson JG.

Amgen's cholesterol drug Repatha has ... it the first in the new PCSK9 inhibitor class approved anywhere in the world. Repatha (evolocumab) is a human monoclonal antibody that inhibits PCSK9 ...

At the moment no oral PCSK9 drugs have started clinical development, and AZ says it intends to start clinical testing of Dogma’s candidate next year. There are two antibodies already on the mark ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic bleeding complications linked to ticagrelor, a common drug used to treat patients ...

Ebdarokimab is the company's first Class 1 new drug approved for autoimmune diseases and the second non-oncology new drug to receive marketing approval, following ebronucimab (PCSK9). This approval ...

Non-oncology expansion: ebronucimab (PCSK9) approved ... while advancing novel treatments such as anti-CD47 monoclonal antibody, antibody drug conjugates ("ADCs") and bispecific ADCs.